In vitro to in vivo extrapolation to support the development of the next generation risk assessment (NGRA) strategy for nanomaterials

The in vitro to in vivo extrapolation models (IVIVE) can support the development of the Next Generation Risk Assessment through integration the AOP-anchored strategy for in vitro assays selection with the PBPK models.